cIAP1 Ligand-Linker Conjugates 12 are primarily utilized in the field of targeted cancer therapy. These compounds are designed to specifically bind to cellular inhibitor of apoptosis protein 1 (cIAP1), which plays a crucial role in regulating cell survival and apoptosis. By targeting cIAP1, these conjugates can induce apoptosis in cancer cells, making them a promising tool for developing anti-cancer drugs. They are often used in research to study the mechanisms of apoptosis and to develop novel therapeutic agents that can selectively kill cancer cells while sparing normal cells. Additionally, these conjugates are employed in the design of proteolysis-targeting chimeras (PROTACs), which are a new class of drugs that degrade specific proteins involved in disease processes. This makes cIAP1 Ligand-Linker Conjugates 12 valuable in both basic research and the development of innovative cancer treatments.